DNA and Gene Chip Global Market Report 2024

The global dna and gene chip market has grown rapidly in recent years. It will grow from $7.38 billion in 2023 to $8.4 billion in 2024 at a compound annual growth rate (CAGR) of 13.9%. The growth observed in the historical period can be attributed to factors such as advancements in genomic research, the rise of personalized medicine, milestones achieved in the Human Genome Project, and the identification of disease biomarkers that contribute to drug discovery and development.

The global dna and gene chip market is expected to see rapid growth in the next few years. It will grow to $13.7 billion in 2028 at a compound annual growth rate (CAGR) of 13.0%. The anticipated growth in the forecast period can be attributed to advancements in precision medicine, the expansion of biomarker discovery, the growth of personalized therapeutics, the application of genomics in cancer research, and an increase in research funding. Major trends in the forecast period encompass technological advancements, product innovations, regulatory framework and compliance considerations, a growing focus on rare diseases, and the continuous reduction in costs associated with genomics research and applications.

The DNA and gene chip market is experiencing substantial growth, primarily fueled by the escalating demand for early cancer detection. Cancer, a pervasive health concern, prompts an urgent need for technologies facilitating timely identification. DNA and gene chips play a pivotal role in measuring gene expression, understanding genetic landscapes, and assessing genomic regulatory elements in cancer cells. Notably, the American Cancer Society estimates approximately 1.9 million new cancer cases and 609,360 deaths in the United States for 2022, emphasizing the critical role of DNA and gene chips in advancing early cancer detection.

The DNA and gene chip market is poised for growth due to the increasing emphasis on personalized medicine. Personalized medicine leverages an individual's genetic profile to tailor disease prevention, diagnosis, and treatment decisions. DNA and gene chips serve as crucial tools in analyzing genetic profiles, aiding in identifying disease risks and determining personalized treatment options. In 2021, the FDA's CDER approved 50 new molecular entities, with 35% classified as personalized medicines by The Personalized Medicine Coalition, underscoring the market's trajectory towards personalized healthcare solutions.

A prevailing trend in the DNA and gene chip market is the emergence of strategic partnerships and collaborations. Companies within the sector are increasingly seeking alliances to fortify their market positions. For instance, Avesthagen Limited entered a four-year strategic partnership with Wipro Limited in June 2022 for a genomics sequencing project related to lung cancer. Similarly, Thermo Fisher Scientific collaborated with Qatar Genome Program in May 2022 to develop a genotyping array for pan-Arab populations. These collaborations exemplify a strategic approach to advancing genomic research and precision medicine initiatives.

Major players in the DNA and gene chip market are driving advancements through groundbreaking genotyping chips. Noteworthy is Ÿnsect's introduction of Axiom YNS_Mol1, the world's first genotyping chip designed for insect breeding, specifically targeting the Tenebrio Molitor mealworm. In collaboration with Thermo Fisher Scientific, Ÿnsect aims to revolutionize insect breeding for sustainable food and pet food. Axiom YNS_Mol1 analyzes genetic characteristics, fostering genomic diversity, and enhancing traits crucial for sustainable insect production. This innovative stride aligns with Ÿnsect's commitment to advancing entomoculture and addressing environmental challenges through sustainable solutions.

In October 2021, Schott Minifab, an Australia-based manufacturer specializing in microfluidic and medical devices, successfully acquired Applied Microarrays Inc. The financial details of the transaction were not disclosed. This strategic acquisition is anticipated to enhance Schott's bioscience capabilities, particularly in the field of DNA microarrays, and expand its biosensor printing capabilities. Applied Microarrays Inc., the acquired company, is a US-based firm known for its expertise in DNA microarray manufacturing, including the development of DNA and protein biosensors, and other microarrays. The acquisition aligns with Schott Minifab's commitment to advancing its capabilities in the field of microfluidics and bioscience technologies.

Major companies operating in the dna and gene chip market report are PerkinElmer Inc., Illumina Inc., Thermo Fisher Scientific Inc., Macrogen Inc., Agilent Technologies Inc., Greiner Bio-One International GmbH, CapitalBio Corporation, Microarrays Inc., bioMérieux SA, Applied Microarrays Inc., Biometrix Technology Inc., Oxford Gene Technology IP Limited, Affymetrix Inc., Bioneer Corporation, Eurofins MWG Operon LLC, F. Hoffmann-La Roche Ltd., QIAGEN N.V., Bio-Rad Laboratories Inc., Arrayit Corporation, BioChain Institute Inc., Cepheid, Clontech Laboratories Inc., Eppendorf AG, Fluidigm Corporation, GE Healthcare, Genisphere LLC, Gyros Protein Technologies AB, Hitachi High-Technologies Corporation, LC Sciences, and Luminex Corporation.

North America was the largest region in the DNA and gene chip market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dna and gene chip market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dna and gene chip market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The main types of DNA and gene chips include oligonucleotide DNA (O-DNA), complementary DNA (C-DNA), and other variations. Oligonucleotide DNA comprises short single- or double-stranded DNA or RNA fragments with three to twenty nucleotides. Products associated with this technology include consumables and instruments, with applications ranging from cancer diagnostics, gene expression, proteomics, genomics, drug discovery, to agrigenomics. End-user industries involved encompass academic and government research institutes, biotechnology and pharmaceutical companies, hospitals and diagnostics centers, among others.

This report provides DNA and gene chips market statistics, including DNA and gene chips industry global market size, regional shares, competitors with a DNA and gene chips market share, detailed DNA and gene chips market segments, market trends and opportunities, and any further data you may need to thrive in the DNA and gene chips industry. This DNA and gene chips market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The DNA and gene chip market consists of sales of instrumentation and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.